Press Releases

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

2013
Dec 2013 | Download as pdf

Soluble Therapeutics Inc. has a second cash infusion that will help the company continue its work in protein-based pharmaceuticals as well as more

Dec 2013 | Download as pdf

StemBioSys, a San Antonio-based bioscience startup, is looking to raise $8 million in new Series A investor funding. The company has already secured more

29 Nov 2013 | Download as pdf

Medical-device firm Xenex attracts big Investment. When Rackspace Hosting co-founder Morris Miller more

25 Nov 2013 | Download as pdf

Xenex CEO expects 2013 revenues to be north of $20 Million. Xenex Disinfection Services’ Morris Miller expects more

21 Nov 2013 | Download as pdf

Xenex Secures $11.3 Million in Funding; Superbug Zapping Robot Enhances Patient Safety by Eliminating Pathogens that Cause Hospital Infections more

14 Nov 2013 | Download as pdf

DNAtrix Announces Treatment of First Patient in Study with Recurrent Glioblastoma Using DNX-2401 and Temozolomide more

Sept 2013 | Download as pdf

Medical Innovation iTClamp Hemorrhage Control System Used for First Time in United States more

Aug 2013 | Download as pdf

BiO2 Medical Executes Full Commercialization in the United Kingdom Partnering with United Drug Medical (UDM) as an Exclusive Distributor for the Angel® Catheter more

July 2013 | Download as pdf

DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus more

July 2013 | Download as pdf

ArthroCare Announces Acquisition of ENTrigue Surgical, Inc more

May 2013 | Download as pdf

Vidacare projects big revenue spike for 2013 more

May 2013 | Download as pdf

BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval more

May 2013 | Download as pdf

Medical Device Firm iTraumaCareTM Receives FDA 510(k) Clearance for iTClampTM Hemorrhage Control System more

May 2013 | Download as pdf

BiO2 Medical's IDE Application for the Angel(TM) Catheter Receives FDA Approval more

March 2013 | Download as pdf

Woman, 80, gets new blood clot prevention device more

Feb 2013 | Download as pdf

BioDtech, Inc. Issued New United States Patent.

BIRMINGHAM, Ala.--(BUSINESS WIRE)--BioDtech, Inc., a biotechnology company engaged in the development of cutting-edge products for the endotoxin market, announced that it has been granted a patent, by the United States patent office (No. 8,349,570), protecting methods of endotoxin detection. The patent, entitled “Enhancing Endotoxin Detection,” covers the company’s EndoPrepTM and ESPTM technologies for the use of accurate endotoxin detection in biopharmaceuticals and human plasma, respectively.

“The technology covered by this patent has broad applications that enable better safety and efficacy for biotherapeutics and monitoring of inflammation based diseases”
This is the second patent issued to BioDtech for the protection of their intellectual property designed to detect Gram-negative bacteria in a sample, then remove and neutralize endotoxins, depending on their specific requirements.

“The technology covered by this patent has broad applications that enable better safety and efficacy for biotherapeutics and monitoring of inflammation based diseases,” stated Dr. Michael Pepe PhD, President and Chief Executive Officer of BioDtech. “The company is currently pursuing the potential use of this technology for the quality control and production of biotherapeutics as well as diagnostic monitoring of gastrointestinal diseases and Gram-negative bacterial infections,” added Pepe.

About BioDtech, Inc.

BioDtech, Inc. was founded in 2003 to accelerate the development of technologically advanced products for the endotoxin market. It develops and markets a line of reagents and systems globally for the detection, neutralization and removal of endotoxin in injectable drugs, pharmaceutical grade water, medical devices, environmental samples and surfaces. BioDtech’s goal is to monitor endotoxin in the progression of multiple disease states related to inflammation.

BioDtech has a license agreement with the National University of Singapore for the exclusive worldwide licensing rights to develop specific research products and technology as related to endotoxin detection, neutralization and removal. It also has strategic partnerships with biopharmaceutical, pharmaceutical and medical device companies that utilize BioDtech technology with their existing portfolio of products.

For more information about BioDtech, visit http://www.biodtechinc.com back

Jan 2013 | Download as pdf

Successful Completion of Santalis Pharmaceuticals Initial Clinical Trials more